SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001193125-18-117045
Filing Date
2018-04-13
Accepted
2018-04-13 17:17:02
Documents
10
Period of Report
2018-06-05

Document Format Files

Seq Description Document Type Size
1 PRE 14A d563605dpre14a.htm PRE 14A 375854
2 GRAPHIC g563605g35r64.jpg GRAPHIC 27664
3 GRAPHIC g563605g91u41.jpg GRAPHIC 28978
4 GRAPHIC g563605img10.jpg GRAPHIC 46468
5 GRAPHIC g563605img2.jpg GRAPHIC 44571
6 GRAPHIC g563605img3.jpg GRAPHIC 8532
7 GRAPHIC g563605img4.jpg GRAPHIC 2048
8 GRAPHIC g563605img5.jpg GRAPHIC 20257
9 GRAPHIC g563605img8.jpg GRAPHIC 1518
10 GRAPHIC g563605img9.jpg GRAPHIC 39687
  Complete submission text file 0001193125-18-117045.txt   680355
Mailing Address 257 SIMARANO DRIVE SUITE 101 MARLBOROUGH MA 01752
Business Address 257 SIMARANO DRIVE SUITE 101 MARLBOROUGH MA 01752 (508) 767-3861
RXi Pharmaceuticals Corp (Filer) CIK: 0001533040 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-36304 | Film No.: 18755001
SIC: 2834 Pharmaceutical Preparations